Company: Proclara Biosciences
Drug Type: Protein Biologic
Conditions: Alzheimer’s disease, Parkinson’s disease
Mechanism Type: Proteostasis, Protein misfolding modulator
Mechanism: The company’s technology revolved around the General Amyloid Interaction Motif (GAIM) technology that simultaneously targets multiple misfolded proteins or amyloids. The GAIM technology are able to both prevent the formation of new toxic protein aggregates and also clear existing aggregates in the form of both soluble oligomers and insoluble fibers, such as plaques and tangles. NPT088 is the GAIM motif fused to a portion of a human antibody, which can be easily administered to patients. This mechanism of action suggest that the GAIM technology could also be beneficial in ALS.
U.S. Status for ALS: N/A
 Neurophage. Our Science, Papers and Posters. Neurophage, 2015. Accessed 11 Mar 2016 from http://neurophage.com/science/papers-posters/.
 Hunting For Brain Plaques, Neurophage Turns to a Virus. Fidler, B. Xconomy, 31 Jan 2016. Accessed 11 Mar 2016 from http://www.xconomy.com/boston/2014/01/31/hunting-for-brain-plaques-neurophage-turns-to-a-virus/.
Last updated February 28th, 2019